Thiazolidinediones and Glucagon-like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study

Hepatology

Nonalcoholic Fatty Liver Disease and the Incidence of Myocardial Infarction: A Cohort Study

J Gastroenterol Hepatol.

Sinn DH, Kang D, Chang Y, Ryu S, Cho SJ, Paik SW, Song YB, Pastor-Barriuso R, Guallar E, Cho J, Gwak GY

doi: 10.1111/jgh.14856.

Hepatology

Nonalcoholic Fatty Liver Disease Increases Risk of Incident Chronic Kidney Disease: a Systematic Review and Meta-Analysis

Metabolism.

Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G

doi: 10.1016/j.metabol.

Hepatology

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Liver Transpl

Younossi ZM

doi: 10.1002/lt.25003.

Gastrointestinal CancerHepatology

The Risk of Incident Extrahepatic Cancers is higher in Nonalcoholic Fatty Liver Disease than Obesity - a Longitudinal Cohort Study

J Hepatol.

Allen AM, Hicks SB, Mara KC, Larson JJ, Therneau TM

doi: 10.1016/j.jhep.2019.08.018.

Hepatology

Women With Nonalcoholic Fatty Liver Disease Lose Protection Against Cardiovascular Disease: A Longitudinal Cohort Study

Am J Gastroenterol.

Allen AM, Therneau TM, Mara KC, Larson JJ, Watt KD, Hayes SN, Kamath PS

doi: 10.14309/ajg.0000000000000401.

Hepatology

Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study

Nutr Metab Cardiovasc Dis

Morieri ML, Targher G, Lapolla A, D'Ambrosio M, Tadiotto F, Rigato M, Frison V, Paccagnella A, Simioni N, Avogaro A, Fadini GP

doi: 10.1016/j.numecd.2021.08.049

Further Publications

Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease; A Nationwide Cohort Study

J Gastroenterol Hepatol

Pyo JH, Kim TJ, Lee H, Choi SC, Soo-Jin C, Choi YH, Min YW, Min BH, Lee JH, Kang M, Lee YC, Kim JJ

doi: 10.1111/jgh.15236

Hepatology

Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study

Clin Gastroenterol Hepatol.

Baratta F, Pastori D, Angelico F, Balla A, Paganini AM, Cocomello N, Ferro D, Violi F, Sanyal AJ, Del Ben M

doi: 10.1016/j.cgh.2019.12.026.

Hepatology

Women have Lower Risk of Nonalcoholic Fatty Liver Disease but Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis

Clin Gastroenterol Hepatol.

Balakrishnan M, Patel P, Dunn-Valadez S, Dao C, Khan V, Ali H, El-Serag L, Hernaez R, Sisson A, Thrift AP, Liu Y, El-Serag HB, Kanwal F

doi: 10.1016/j.cgh.2020.04.067.

Related content

Nonalcoholic Fatty Liver Disease and the Incidence of Myocardial Infarction: A Cohort Study

Nonalcoholic Fatty Liver Disease Increases Risk of Incident Chronic Kidney Disease: a Systematic Review and Meta-Analysis

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

The Risk of Incident Extrahepatic Cancers is higher in Nonalcoholic Fatty Liver Disease than Obesity - a Longitudinal Cohort Study

Women With Nonalcoholic Fatty Liver Disease Lose Protection Against Cardiovascular Disease: A Longitudinal Cohort Study

Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study

Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease; A Nationwide Cohort Study

Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study

Women have Lower Risk of Nonalcoholic Fatty Liver Disease but Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis